Accunea
MedTech startup Accunea has developed RenoSure, a new device that has been designed to 'transform' kidney care according to the company, and increase the number of organs available for transplantation.
Accunea says the device assesses organ condition accurately and in real time before kidney transplants. The company says it believes that the device can prevent good organs from going to waste and save lives.
Accunea claims that RenoSure will reduce strain on health services and improve patient outcomes by using unique technology which is able to monitor multiple biomarkers of kidney function and metabolism.
This would allow doctors to assess the health of a donated organ and decide whether to use it based on objective data. This would help them to make the difficult decision of whether to go ahead with a transplant in the operating theatre, significantly increasing the number of transplants and preventing organ wastage.
“There are 100,000 kidney transplants worldwide every year, but currently there’s no objective test for the viability of an organ, which leaves thousands of donated kidneys going to waste,” said Rob Learney, CEO of Accunea.
The small in-vitro device is easy to use, blood free, and doesn’t require drug administration says the company. This means that it can fit into existing care pathways, in an environment which is highly pressurised.
RenoSure’s latest iteration includes a patented sensor system, which provides real time data readings for clinicians, so they can fully understand the health of a kidney at the exact moment they make the decision to transplant.
“At the moment we’re failing patients in need of a transplant, who are left suffering from a chronic illness which will kill them, or with their lives restricted by dialysis. We’re failing health services too, which are put under additional pressure by every failed transplant and every patient staying on dialysis for longer than necessary” said Learney.
“Anything we can do to give clinicians extra information and data in the operating theatre can only be a good thing for improving the decision-making process too.”
Accunea has secured 200,000 EUR of funding from the Microfluidics Innovation Hub, with the potential for more investment from other sources.
“RenoSure is a truly transformative device for kidney transplant patients and clinicians, so we’re delighted to see momentum that it’s gaining,” added Learney.
“With improvements to our sensor technology, and the prospect of new funding on the horizon we’re excited to continue helping to improve patients’ experience of kidney care and prevent organs from being wasted on a larger scale.”
Dr. Divesh Baxani Kamal at the Microfluidics Innovation Hub added: “We’re excited to welcome Accunea to our stand at COMPAMED. Our collaboration really showcases how the collective expertise of our partners can be leveraged to accelerate product development. The earlier the product is on the market, the more kidneys can be saved.
“By using microfluidics technology, devices like RenoSure are changing approaches to kidney care, and improving outcomes for patients. This can only be a good thing, which we want to champion and help to grow,"
Accunea is exhibiting on the Microfluidics Innovation Hub stand, Hall 8A, Booth K32 at COMPAMED 2024, from Monday 11 to Thursday 14 November.
